The FDA has approved suzetrigine (Journavx – Vertex), a selective sodium channel blocker, for oral treatment of moderate to severe acute pain in adults. Suzetrigine is the first sodium channel blocker to be approved in the US for this indication and the first oral nonopioid drug to be approved for treatment of pain in over 25 years.
STANDARD TREATMENT ― Nonopioid drugs are preferred for treatment of pain. In patients with moderate to severe acute pain, use of an NSAID plus acetaminophen may be at least as effective as an oral opioid combined with acetaminophen or even an injected opioid....
- Nemolizumab (Nemluvio) for Atopic Dermatitis
- Vadadustat (Vafseo) for Anemia of Chronic Kidney Disease
- Tirzepatide (Zepbound) for Obstructive Sleep Apnea
- In Brief: New Warning for the RSV Vaccines Arexvy and Abrysvo
- In Brief: Anaphylaxis with Glatiramer Acetate
- Comparison Chart: Interleukin (IL) Receptor Antagonists for Atopic Dermatitis (online only)
- Cosibelimab (Unloxcyt) for Cutaneous Squamous Cell Carcinoma (online only)
- Ensartinib (Ensacove) for Non-Small Cell Lung Cancer (online only)
- Remestemcel-L (Ryoncil) for Graft-Versus-Host Disease (online only)
ISSUE
Disruption of tear-film homeostasis (altered composition, reduced production, rapid evaporation) and resulting ocular surface inflammation cause the discomfort and blurred vision of dry eye disease. Many cases are caused by tear evaporation due to meibomian gland dysfunction. Other precipitating factors can include lacrimal gland dysfunction, poor eyelid function, environmental factors, extended screen time, inflammatory conditions such as Sjögren's syndrome, and use of some ocular or systemic drugs such as antihistamines, retinoids, or selective serotonin reuptake inhibitors (SSRIs). Benzalkonium chloride, a preservative used in some eye drops, can cause eye irritation and exacerbate symptoms of dry eye disease; use of preservative-free ophthalmic preparations is preferred. Dry eye disease is most prevalent in females and older adults, but its incidence in young people is …